PDF(1294 KB)
Value of lactate dehydrogenase in predicting refractory Mycoplasma pneumoniae pneumonia in children: an evaluation based on decision curve analysis and dose-response analysis
ZHENG Xue-Xiang, LIN Ji-Lei, DAI Ji-Hong
Chinese Journal of Contemporary Pediatrics ›› 2020, Vol. 22 ›› Issue (2) : 112-117.
PDF(1294 KB)
PDF(1294 KB)
Value of lactate dehydrogenase in predicting refractory Mycoplasma pneumoniae pneumonia in children: an evaluation based on decision curve analysis and dose-response analysis
Objective To study the value of lactate dehydrogenase (LDH) in predicting refractory Mycoplasma pneumoniae pneumonia (RMPP) in children. Methods Propensity score matching was used to select 73 children with RMPP (refractory group) and 146 children with non-refractory Mycoplasma pneumoniae pneumonia (common group). The logistic regression analysis, restricted cubic spline model, and decision curve analysis were used to analyze the clinical value of LDH in predicting RMPP. Results There were significant differences in the incidence of high fever, white blood cell count, platelet count, percentage of neutrophils, and serum levels of C-reactive protein, procalcitonin, hemoglobin, albumin, glutamic-pyruvic transaminase, aspartate aminotransferase and LDH (P < 0.05). There were also significant differences between the two groups in the Mycoplasma pneumoniae-DNA load in nasopharyngeal aspirates and the incidences of pleural effusion, pulmonary consolidation, atelectasis, shortness of breath and skin lesions (P < 0.05). The multivariate logistic regression analysis showed that high fever, hemoglobin level, LDH level, and pulmonary consolidation were independent predictive factors for RMPP (OR=10.097, 0.956, 1.006, and 3.756; P < 0.05). The results of the restricted cubic spline analysis showed a non-linear dose-response relationship between the continuous changes of LDH and the development of RMPP (P < 0.01). The decision curve analysis showed that LDH had an important clinical value in predicting RMPP. Conclusions LDH is an independent predictive factor for the development of RMPP and its intensity of association with the development of RMPP exhibits a non-linear dose-response relationship.
Refractory Mycoplasma pneumoniae pneumonia / Lactate dehydrogenase / Dose-response analysis / Decision curve analysis / Child
[1] 柯莉芹, 王凤美, 李银洁, 等. 儿童肺炎支原体肺炎流行病学特征[J]. 中国当代儿科杂志, 2013, 15(1):33-36.
[2] Biondi E, McCulloh R, Alverson B, et al. Treatment of mycoplasma pneumonia:a systematic review[J]. Pediatrics, 2014, 133(6):1081-1090.
[3] Yang HJ, Song DJ, Shim JY. Mechanism of resistance acquisition and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children[J]. Korean J Pediatr, 2017, 60(6):167-174.
[4] 刘雪梅, 徐飞, 谈华, 等. 进展为难治性支原体肺炎的危险因素分析[J]. 山东医药, 2018, 58(28):80-82.
[5] 张巧. 儿童难治性肺炎支原体肺炎发病机制及治疗研究进展[J]. 儿科药学杂志, 2019, 25(6):61-63.
[6] Tamura A, Matsubara K, Tanaka T, et al. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children[J]. J Infect, 2008, 57(3):223-228.
[7] 潘艳艳, 孙永超, 张洪霞. 难治性支原体肺炎患儿血清铁蛋白水平变化及其意义[J]. 山东医药, 2015, 55(38):68-69.
[8] 周忠霞, 王霆, 王辉. 乳酸脱氢酶在成人社区获得性肺炎严重程度诊断中的价值[J]. 临床肺科杂志, 2017, 22(6):1026-1029.
[9] 杜玉秀, 马香萍, 多力坤·木扎帕尔. 病毒性肺炎患儿血清糖蛋白、乳酸脱氢酶变化及意义[J]. 临床儿科杂志, 2012, 30(2):138-140.
[10] 李宁, 陈言钊, 周克英. 乳酸脱氢酶在儿童难治性肺炎支原体肺炎诊断和治疗中的意义[J]. 中国小儿急救医学, 2017, 24(4):305-308.
[11] Liu TY, Lee WJ, Tsai CM, et al. Serum lactate dehydrogenase isoenzymes 4 plus 5 is a better biomarker than total lactate dehydrogenase for refractory Mycoplasma pneumoniae pneumonia in children[J]. Pediatr Neonatol, 2018, 59(5):501-506.
[12] 中华医学会儿科学分会呼吸学组, 《中华实用儿科临床杂志》编辑委员会. 儿童肺炎支原体肺炎诊治专家共识(2015年版)[J]. 中华实用儿科临床杂志, 2015, 30(17):1304-1308.
[13] 辛德莉,李丹,米佳.LAMP®技术在肺炎支原体快速检测中的应用[J]. 中国医疗器械信息, 2014(7):16-18.
[14] Kakuya F, Kinebuchi T, Fujiyasu H, et al. Genetic point-of-care diagnosis of Mycoplasma pneumoniae infection using LAMP assay[J]. Pediatr Int, 2014, 56(4):547-552.
[15] Fitzgerald M, Saville BR, Lewis RJ. Decision curve analysis[J]. JAMA, 2015, 313(4):409-410.
[16] Lu A, Wang C, Zhang X, et al. Lactate dehydrogenase as a biomarker for prediction of refractory Mycoplasma pneumoniae pneumonia in children[J]. Respir Care, 2015, 60(10):1469-1475.
[17] Izumikawa K, Izumikawa K, Takazono T, et al. Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia:a review of the Japanese literature[J]. J Infect Chemother, 2014, 20(3):181-185.
[18] 李远光, 罗明鑫, 解启莲. 难治性支原体肺炎患儿早期乳酸脱氢酶、T细胞亚群的检测及临床意义[J]. 临床肺科杂志, 2017, 22(7):1276-1278.
[19] Inamura N, Miyashita N, Hasegawa S, et al. Management of refractory Mycoplasma pneumoniae pneumonia:utility of measuring serum lactate dehydrogenase level[J]. J Infect Chemother, 2014, 20(4):270-273.
